• Explore /
  • Poster
  • / Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

Abstract Poster

Authors

Federico Innocenti

Federico Innocenti

University of North Carolina at Chapel Hill, Chapel Hill, NC

Federico Innocenti , Akram Yazdani , Xueping Qu , Fang-Shu Ou , Scott Van Buren , Omar Kabbarah , Charles David Blanke , Alan P. Venook , Heinz-Josef Lenz , Benjamin Garrett Vincent

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3515)

DOI

10.1200/JCO.2021.39.15_suppl.3515

Abstract #

3515

Abstract Disclosures

Similar Posters

First Author: Scott Kopetz

First Author: Scott Kopetz

First Author: Kanwal Pratap Singh Raghav

First Author: Vanessa Wong